Objective: To observe the effect of Huangoki capsule combined with mortemycophenolate and prednisone in the treatment of children with henoch-schonlein purpura nephritis. Methods: 80 patients with HSPN who received treatment in our hospital from January 2022 to December 2023 were selected as the study objects. The children were divided into control group and observation group with 40 cases in each group by random number table method. The control group was treated with mycophenolate morpheate + prednisone; Observation group was treated with yellow sunflower capsule on the basis of control group. The duration of major symptoms, urinary routine [24h urinary protein (UTP) and urinary red blood cell count (URBC) levels], immune function [immunoglobulin (Ig) A, IgG, IgM levels] and the occurrence of adverse reactions were analyzed and compared between the two groups. Results: The disappearance time of clinical symptoms of arthralgia, abdominal pain, hematuria, proteinuria and rashes in observation group was significantly shorter than that in control group (P < 0.005). After 6 months of treatment, UTB and URBC in both groups were significantly lower than before treatment, and UTB and URBC in the observation group were significantly lower than those in the control group (P < 0.05). After 6 months of treatment, the levels of IgA, IgG and IgM in both groups were significantly higher than before treatment, and the levels of IgA, IgG and IgM in the observation group were significantly higher than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: The combination of Huangoki capsule with mortemycophenate + prednisone in the treatment of HSPN children can promote the remission of clinical symptoms, improve immune function, reduce UTB and URBC levels, and the drug is safe.